The last 18 months have challenged the resilience of the planet, organizations and individuals. Jonas Salk, the inventor of the Polio vaccine, at another time of great change and disruption, asked the question “Are we being good ancestors?” He was nudging humanity towards ethical choices, perceiving the long and short term impacts for both themselves and future generations.
Desh Bandhu Gupta, with a few other leaders of his generation, are good ancestors; in a world skeptical of India’s technological prowess, their choices made India the pharmacy for the world. The role our globally competitive pharmaceutical industry has played in the war against COVID-19 is part of this legacy. DBG is a great ancestor for Lupin. His optimism, integrity, vision and zest for technology at affordable prices, endures in a company that operates in 50 countries, and a foundation that serves millions of Indians.
Resilience, an organization’s ability to persist, adapt and transform while retaining its core values, is in Lupin’s DNA. Our DNA scribing comes from DBG’s values; making us a people-centric organization, deploying technology responsibly, and executing speedily. Despite COVID-19 challenging all forms of execution, Lupin now has a stronger platform via reimagination, digitization, and innovation.
DBG would be so proud today. Pharma 4.0 is grounded in his vision of a better world, pioneering pathways in medicine, a diverse product portfolio, and an unbeatable team. If strategy is the art of creating inequitable advantages, Lupin has a strong strategy and an exciting future ahead.
COVID has shown that India rises to challenges, but she needs to be stronger. Lupin re-commits to solving India’s health challenges and taking DBG’s legacy to the world — not solely a business, but a vehicle to do good for society. We can only hope that future generations speak of us, as we speak of our ancestors.